D-0069-2021 Class II Terminated
FDA drug recall D-0069-2021 was initiated by Teva Pharmaceuticals USA on Oct 28, 2020 and is designated Class II. Reason for recall: Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing. The recall status is terminated (terminated Aug 26, 2021). Affected quantity: 133,829 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 18, 2020
- Initiation Date
- Oct 28, 2020
- Termination Date
- Aug 26, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 133,829 bottles
Product description
Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories, FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054, NDC 0591-2245-22.
Reason for recall
Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.
Distribution pattern
Nationwide in the U.S. and PR
Code information
Lot #s: 1342498A, Exp. 12/2020; 1342499A, Exp. 01/2021; 1354638A, Exp. 03/2021; 1354639A, 1358274A, 1358448A, 1364618A, 1369884A, Exp. 05/2021; 1366195A, 1369885A, 1373570A, Exp. 06/2021; 1373571A, Exp. 07/2021; 1388571A, Exp. 01/2022; 1395725A, 1396585A, 1397550A, 1399389A, Exp. 04/2022; 1403885A, 1403886A, Exp. 06/2022.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0069-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026